Collegium Pharmaceutical shares have risen around 12% over the past three months, driven by strong performance of its ADHD franchise and the recent acquisition of Azstarys. Jornay PM, the company's evening-dosed ADHD therapy, recorded more than 206,000 prescriptions in the first quarter of 2026, up 14% year over year, with sales increasing 36%. The acquisition of Azstarys from Corium Therapeutics, completed last month, adds the first and only ADHD treatment combining immediate-release and long-acting medicines in a single capsule, and is expected to be immediately accretive to earnings. Collegium raised its 2026 product revenue guidance to a range of $865 million to $895 million, up from prior guidance of $805 million to $825 million. The company also benefits from a stable pain management portfolio including Xtampza ER, Belbuca, Nucynta ER, Nucynta IR, and Symproic.
Amarin Corporation PLC
Immunocore Holdings LtdCollegium Pharmaceutical IncAzstarys acquisition expected to be immediately accretive to earnings; raised 2026 revenue guidance.
Liquidia Technologies Inc